Lessons learned from d-cycloserine: The promise and limits of drug facilitation of exposure therapy

Journal of Clinical Psychiatry

Volumn 74, Issue 4, 2013, Pages 415-416

  Rodebaugh, Thomas L ^a   Lenze, Eric J ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOSERINE; PLACEBO;

ANXIETY DISORDER; ARTICLE; COGNITIVE THERAPY; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; MEDICAL RESEARCH; META ANALYSIS (TOPIC); NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PSYCHOTHERAPY; SINGLE DRUG DOSE; SOCIAL PHOBIA;

EID: 84876558289     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13ac08464     Document Type: Article

References (20)

1. Davis M, Ressler K, Rothbaum BO, et al. Biol Psychiatry. 2006;60(4):369-375.
2. Lepine J-P. J Clin Psychiatry. 2002;63(suppl 14):4-8.
3. Department of Veterans Affairs. PTSD Treatment Programs in the US Department of Veteran Affairs. http://www.ptsd.va.gov/public/pages/va- ptsdtreatment-programs. Updated July 2, 2012. Accessed August 27, 2012.
4. Davis M. Dialogues Clin Neurosci. 2011;13(4):463-474.
5. Norberg MM, Krystal JH, Tolin DF. Biol Psychiatry. 2008;63(12):1118-1126.
6. Chasson GS, Buhlmann U, Tolin DF, et al. Behav Res Ther. 2010;48(7):675-679.
7. Bontempo A, Panza KE, Bloch MH. J Clin Psychiatry. 2012;73(4):533-537.
8. Pollack MH. d-Cycloserine augmentation of CBT for social anxiety disorder: results from an RCT. Presented at: 52nd Annual NCDEU Meeting; May 29, 2012; Phoenix, AZ.
9. Werner-Seidler A, Richardson R. Biol Psychiatry. 2007;62(10):1195-1197.
10. Silvestri AJ, Root DH. Physiol Behav. 2008;93(1 -2):274-281.
11. Kalisch R, Holt B, Petrovic P, et al. Cereb Cortex. 2009;19(1):187-196.
12. de Kleine RA, Hendriks G-J, Kusters WJC, et al. Biol Psychiatry. 2012;71(11):962-968.
13. Litz BT, Salters-Pedneault K, Steenkamp MM, et al. J Psychiatr Res. 2012;46(9):1184-1190.
14. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Arch Gen Psychiatry. 2004;61(11):1136-1144.
15. Kola I, Landis J. Nat Rev Drug Discov. 2004;3(8):711-715.
16. Graham BM, Langton JM, Richardson R. Br J Pharmacol. 2011;164(4):1230- 1247.
17. Wells A, Clark DM, Salkovskis P, et al. Behav Ther. 1995;26(1):153-161.
18. Wells A, Papageorgiou C. Behav Ther. 1998;29(3):357-370.
19. Rodebaugh TL, Heimberg RG, Schultz LT, et al. J Anxiety Disord. 2010;24(7):663-671.
20. Rodebaugh TL, Levinson C A, Lenze EJ. A high-throughput clinical assay for testing drug facilitation of exposure therapy [published online ahead of print January 2, 2013]. Depress Anxiety.